Treatment Outcomes in a Specialized Opioid Maintenance Program for Prescription Opioid Use Disorder in Israel
Substance Abuse and Rehabilitation · 2026-03 · Volume 17 · 1-12
DOI: 10.2147/sar.s584953 ↗Kurz gefasst
Fachartikel in der Zeitschrift Substance Abuse and Rehabilitation, 2026-03. Verfasst von Zehavit Mendelson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Miriam & Sheldon G. Adelson Clinic for Drug Abuse, Treatment & Research, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Themen: Sucht und Abhängigkeit
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Miriam & Sheldon G. Adelson Clinic for Drug Abuse, Treatment & Research, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.
- Gray Faculty of Medical and Health Sciences, Tel-Aviv University, Tel Aviv, Israel.
- Sagol School of Neuroscience, Tel-Aviv University, Tel Aviv, Israel.
ORCID-Profile: Shaul Schreiber, Einat Peles
Zitieren
APA
Mendelson, Z., Sason, A., Schreiber, S., Adelson, M., & Peles, E. (2026). Treatment Outcomes in a Specialized Opioid Maintenance Program for Prescription Opioid Use Disorder in Israel. Substance Abuse and Rehabilitation, Volume 17, 1-12. https://doi.org/10.2147/sar.s584953
Vancouver
Mendelson Z, Sason A, Schreiber S, Adelson M, Peles E. Treatment Outcomes in a Specialized Opioid Maintenance Program for Prescription Opioid Use Disorder in Israel. Substance Abuse and Rehabilitation. 2026;Volume 17:1-12. doi:10.2147/sar.s584953
BibTeX
@article{Mendelson2026,
author = {Mendelson, Zehavit and Sason, Anat and Schreiber, Shaul and Adelson, Miriam and Peles, Einat},
title = {Treatment Outcomes in a Specialized Opioid Maintenance Program for Prescription Opioid Use Disorder in Israel},
journal = {Substance Abuse and Rehabilitation},
year = {2026},
volume = {Volume 17},
pages = {1--12},
doi = {10.2147/sar.s584953}
}
EUVIMED